This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Program Description/Statement of Need
This Interactive Exchange™ educational activity focuses on identification and long-term management of patients with severe asthma. Expert faculty will provide interpretive insights into the role of biomarkers, comorbidity management, and use of targeted biologic therapies, including their own clinical experience with personalizing therapy and engaging patients in shared decision making. Brief video segments will be shown throughout the program to highlight key aspects of severe asthma pathophysiology and the clinical implications for targeted therapies.
The educational design of this activity addresses the needs of clinical immunologists, allergists, and other specialists involved in the management of patients with severe asthma.
Upon completion of this activity, participants will be better able to do the following:
Discuss asthma pathophysiology, including Th2-mediated processes and clinically relevant treatment targets
Implement guideline recommendations related to the identification, comprehensive assessment, and longitudinal management of patients with severe asthma
Describe the mechanistic rationale, published evidence, and prescribing considerations for biologic therapies in severe asthma
Tailor therapeutic regimens for patients with severe asthma based on disease phenotypes, ongoing symptoms and exacerbation risks, treatment-related toxicities, and comorbidities
Engage patients with severe asthma in long-term management planning to reflect treatment goals, clinical and laboratory findings, and potential benefits and risks of available therapeutic options
Conflict Of Interest Disclosure Policy
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Jonathan Corren, MD Associate Clinical Professor of Medicine and Pediatrics David Geffen School of Medicine at UCLA Director, Allergy Medical Clinic Los Angeles, California
Dr. Corren discloses the following: Speakers Bureau: AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC Consultant/Advisor: AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC; Pulmatrix Research Grant: AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC; Stallergenes Greer plc
John J. Oppenheimer, MD (Virtual Professor) Clinical Professor of Medicine, Rutgers New Jersey Medical School Newark, New Jersey Clinician, Atlantic Health System Morristown Medical Center Morristown, New Jersey
Dr. Oppenheimer discloses the following: Consultant/Independent Contractor: AstraZeneca; DBV Technologies; GlaxoSmithKline, Sanofi Grant/Research Support (Adjudication Data and Safety Monitoring Board): AstraZeneca; Novartis
Reynold A. Panettieri, Jr, MD Professor of Medicine, Robert Wood Johnson Medical School Vice Chancellor, Translational Medicine and Science Director, Rutgers Institute for Translational Medicine and Science New Brunswick, New Jersey Emeritus Professor of Medicine, University of Pennsylvania Philadelphia, Pennsylvania
Dr. Panettieri has nothing to disclose.
Sally E. Wenzel, MD Professor of Medicine and Immunology Director, University of Pittsburgh Asthma Institute at UPMC/UPSOM UPMC Chair of Translational Airway Biology Chair, Department of Environmental and Occupational Health Graduate School of Public Health University of Pittsburgh Pittsburgh, Pennsylvania
Dr. Wenzel discloses the following: Consultant/Advisor: AstraZeneca; sanofi-aventis U.S. LLC; Pieris Research Grant: AstraZeneca; GlaxoSmithKline; Novartis Pharmaceuticals Corporation (paid to University Pittsburgh Medical Center); Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Planners' and Managers' Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME/CE activity:
Lindsay Borvansky has nothing to disclose. Andrea Funk has nothing to disclose. Ashley Cann has nothing to disclose. Julia Muino has nothing to disclose. Rose O’Connor, PhD, CHCP, has nothing to disclose. Jim Kappler, PhD, has nothing to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Global Education Group designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee and Refund / Cancellation Policy
There is no fee for this educational activity.
In order to receive credit, participants must complete the preactivity questionnaire, post-test, and program evaluation. Participants must also score at least 66% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.